查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球基準標記市場
市場調查報告書
商品編碼
1217640

2023-2030 年全球基準標記市場

Global Fiducial Markers Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

基準標記，也稱為基準，是用細針插入患者體內以進行放射治療的小型金屬植入物。 尺寸約為3mm。 標記本身很舒服，患者在裡面感覺不到它們。 基準點通常用於接受前列腺癌外照射的患者。 它還用於治療軟組織癌，例如肺癌和頭頸癌。

市場動態

推動全球基準標記市場的主要因素是癌症發病率激增導致對基準製造商的需求增加、輻射意識提高、新興國家對醫學成像的需求增加以及醫療保健成本增加等。

由於癌症患病率激增，對基準製造商的需求增加預計將推動市場增長。

根據世界衛生組織 (WHO) 的數據，到 2022 年，約有 1000 萬人（即約六分之一的死亡人數）將死於癌症，預計到 2020 年癌症將成為全球主要死因。 乳腺癌、肺癌、結腸癌、直腸癌和前列腺癌是最常見的癌症類型。 煙草使用、過度肥胖、飲酒、水果和蔬菜攝入量低以及缺乏運動約佔癌症死亡人數的三分之一。 人乳頭瘤病毒 (HPV) 和肝炎等致癌感染被認為佔低收入和中等收入國家癌症病例的 30%。 通過早期發現和適當的治療，許多腫瘤是可以治癒的。

根據國家癌症研究所的數據，2020 年美國將有 1,806,590 例新的癌症診斷和 606,520 例癌症死亡。. 最常見的癌症是乳腺癌、肺癌和支氣管癌、皮膚黑色素瘤、膀胱癌、非霍奇金淋巴瘤、腎癌和腎盂癌、子宮內膜癌、白血病、胰腺癌、甲狀腺癌、肝癌（按降序排列） 2020 年估計患者人數的順序）。 由於癌症發病率上升，基準生產商進行腫瘤鑑定的潛力正在推動市場。

該產品引起的並發症預計會阻礙市場的增長。

基準標記現在能夠最有效地將藥物輸送到腫瘤，同時對周圍健康組織造成的損害最小。 雖然基準標記在放射治療中具有很大優勢，但它們也存在其他風險。

氣胸和肺出血是最常見的副作用。 當同時進行 FM 植入和活檢取樣時，發現問題的風險更高。 肺部病變佔問題的大部分，所有肺部病變的 FM 移植都是在 CT 引導下進行的。 自限性氣胸、肺出血和咯血屬於非嚴重問題。 最嚴重的副作用是氣胸，需要就醫和住院治療。

COVID-19 影響分析

由於採取了嚴格的封鎖程序和對人員流動的限制，COVID-19 病毒的爆發對基準標記行業的影響微乎其微。 當前的冠狀病毒大流行正在損害醫療保健。 COVID-19 大流行不僅對基準製造商市場產生了重大影響，而且對全球醫療保健系統也產生了重大影響。 根據 Cancer Connect 2020 上的一篇文章，達納—法伯癌症研究所的研究人員診斷出六種最常見的癌症：乳腺癌、結腸癌、肺癌、胰腺癌、胃癌和食道癌。發現在 COVID-19 流行期間癌症減少了 46%。

此外，包括美國疾病控制與預防中心 (CDC) 在內的許多醫療保健專業人員都提倡延遲擇期手術、癌症篩查和其他健康預防服務，除非風險大於收益；建議醫院做好準備用於護理 -19 名患者的基礎設施。 因此，COVID-19 流行病損害了基準生產商的市場。 然而，隨著時間的推移，這種情況有望得到改善。 領先的醫療保健公司正在加緊尋找 COVID-19 疫苗和治療方法，這給世界各地的醫院基礎設施帶來了巨大壓力。 儘管如此，隨著癌症治療的繼續，基準標記物的市場依然強勁。 但是，其中一些已被重新安排或放棄。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 由於癌症發病率迅速上升，基準製造商的需求不斷擴大
      • 輻射意識的提高促進了市場擴張
    • 約束因素
      • 產品引起的並發症預計會阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第7章按產品配置

  • 黃金標記
  • 聚合物標記
  • 碳標記
  • 白金標記
  • 液體標記
  • 其他

第八章應用

  • 放射治療
  • CT/CBCT 掃描
  • MRI/MEG 檢查
  • 內窺鏡超聲檢查
  • 其他

第 9 章按位置

  • 頭部和頸部
  • 乳房
  • 肺
  • 腹部
  • 前列腺
  • 其他

第 10 章最終用戶

  • 醫院
  • 門診手術診所
  • 專科診所
  • 研究所

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第13章公司簡介

  • 波士頓科學公司
    • 公司概況
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Medtronic Plc
  • Nanovi A/S
  • IBA Dosimetry
  • Roper Technologies Inc.
  • Guerbet SA
  • Eckert & Ziegler BEBIG S.A.
  • IZI Medical Products Inc.
  • Naslund Medical AB
  • MediTron SA.

第14章 DataM

簡介目錄
Product Code: DMMI1830

Market Overview

The global fiducial markers market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

Fiducial markers, also referred to as fiducials, are tiny metal implants that are inserted into the body of a patient using a fine needle to direct radiation therapy. They are roughly 3 mm in size. The markers themselves are not uncomfortable, and the patient cannot feel them internally. Patients receiving external beam radiation therapy for prostate cancer are the ones who use fiducials the most frequently. They can, however, also be utilized to direct treatment for additional soft tissue cancer types, such as lung, head, and neck tumors.

Market Dynamics

The major factors driving the global fiducial markersmarket the rising demand for fiducial manufacturers due to a rapid rise in cancer incidences, the market's expansion is being further fuelled by the increased awareness of radiation, rising demand for medical imaging procedures and rising healthcare expenditure in emerging markets.

Rising demand for fiducial manufacturers due to a rapid rise in cancer incidences is expected to drive the market's growth.

According to World Health Organization, in 2022, nearly 10 million deaths, or nearly one in six deaths, will be caused by cancer 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. In low- and lower-middle-income nations, cancer-causing infections, including the human papillomavirus (HPV) and hepatitis, are thought to cause 30% of cancer cases. If caught early and appropriately treated, many tumors are curable.

And according to National Cancer Institute(U.S.A), in the U.S., there will likely be 1,806,590 new cases of cancer diagnosed in 2020, and there will also likely be 606,520 cancer-related deaths. The most prevalent cancers are breast cancer, lung and bronchus cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer (listed in descending order by estimated new cases in 2020). The market is driven by the possibility for the fiducial producers to identify the tumor due to the rise in cancer incidence.

The complications caused by the products are projected to impede the growth of the market.

Fiducial markers has made for the most effective drug delivery to tumors while causing the least amount of damage to surrounding healthy tissues. Fiducial markers have certain additional risks, although having a major benefit in radiation therapy procedures.

Pneumothoraces and pulmonary bleeding were the most frequent side effects. The risk of problems was found to be higher when FM implantation and biopsy sampling were done simultaneously. Lung lesions accounted for the majority of the issues, and all FM implantations for lung lesions were performed under CT guidance. Self-limiting pneumothoraces, pulmonary bleeding, and hemoptysis were among the less severe issues. The most severe side effect was a pneumothorax, which necessitated medical attention and hospitalization.

COVID-19 Impact Analysis

Due to strong lockdown procedures and a restricted flow of personnel, the COVID-19 virus epidemic has had a minimal impact on the fiducial markers sector. The current coronavirus pandemic has harmed healthcare. The COVID-19 pandemic has had a huge influence on the market for fiducial manufacturers as well as on the world's healthcare systems. According to an article in Cancer Connect 2020, researchers from the Dana Farber Cancer Institute found that the six most frequent cancer types-breast, colorectal, lung, pancreatic, gastric, and esophageal cancers-had a 46% decline in diagnoses during the COVID-19 pandemic.

Additionally, it was advised to delay elective surgeries, cancer screenings, and other health prevention services unless the risks outweighed the benefits and to prepare the hospital infrastructure for the care of COVID-19 patients by the Centers for Disease Control and Prevention (CDC) and many other medical professional organizations. The COVID-19 epidemic has thus damaged the market for fiducial producers. However, it is anticipated that things will get better with time. Major healthcare corporations are stepping up their attempts to find potential COVID-19 vaccines and medications, putting tremendous strain on hospital infrastructures worldwide. Despite this, ongoing cancer treatments have kept the market for fiducial markers strong. However, several of the procedures were rescheduled or abandoned.

Segment Analysis

The gold fiducial markers segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The gold fiducial markers segment is the highest market holder in the global fiducial markers market. Gold fiducial markers can also be combined with other metals like titanium, platinum, and nickel for increased effectiveness. For instance, these markers improve visibility in MRI scans when coupled with titanium stripes. Major businesses are increasing their R&D spending to create more efficient products. As an illustration, IBA Dosimetry GmbH introduced the Visicoil linear pure gold fiducial marker, a novel helical-shaped product with a hollow core that lowers the incidence of typical issues such as marker migration and artifacts.

Additionally, in June 2022, Nanovi reported that its liquid fiducial marker, BioXmark, has demonstrated in a clinical study to be technically possible to implant in stomach cancer patients to guide preoperative image-guided radiation therapy (IGRT). It can be difficult to accurately identify the treatment target on daily collected CBCT scans during preoperative IGRT of the stomach. Twelve (12) patients with stomach cancer participated in this clinical investigation from the Amsterdam University Medical Center. The study's objective was to evaluate the technological viability of implanting liquid marker (BioXmark) and gold marker (Visicoil) for preoperative stomach cancer IGRT guidance. The segment drives the market as a response.

Geographical Analysis

North America holds the largest market share in the global Fiducial Markers market.

North America dominates the global fiducial markers market primarily due to its large population, excellent medical infrastructure, and high-income levels. Due to factors such as the rising incidence of cancer, the presence of numerous major players, rising spending on research and development, increasing patient awareness and preference for radiotherapy, favorable reimbursement laws, and technological advancements, North America is anticipated to account for a sizeable portion of the global market for fiducial markers.

The American Association for Cancer Research reports that since the 1990s, the age-adjusted total cancer death rate in the U.S. has been consistently falling. The decrease between 1991 and 2019 means avoiding over 3.5 million cancer deaths. As of January 1, 2022, more than 18 million cancer survivors will live in the U.S., an increase of more than a million over the previous three years. The advancements in the fight against cancer have not benefited all American communities equally.

It'll also increase the need for disease treatment and grow the market. In North America, the U.S. holds the largest proportion of the market for fiducial markers. The Fiducial Markers Market in this area is also anticipated to benefit from cutting-edge radiation techniques, imaging modalities, and well-established healthcare infrastructure.

Competitive Landscape

The Fiducial Markers market is moderately competitive with local and global companies' presence such as Boston Scientific Corporation, Medtronic Plc, Nanovi A/S, IBA Dosimetry, Roper Technologies Inc., Guerbet SA, Eckert & Ziegler BEBIG S.A., IZI Medical Products Inc., Naslund Medical AB and MediTron SAand more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, first Prostate Cancer treatments use Nova Fiducial Markers announced by C4 Imaging. The first prostate cancer therapies using Nova, a multimodality fiducial marker created to improve the precision of cancer treatment, have been announced by C4 Imaging LLC.

Boston Scientific Corporation.

Overview:A medical technology company called Boston Scientific Corp. (Boston Scientific) is engaged in the development, production, and commercialization of devices for several interventional medical specialties. Electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain management, pulmonology, urology, and vascular surgery are among the specialties in which the company sells products. All across the world, Boston Scientific provides services to hospitals, clinics, outpatient facilities, and medical offices.

Product Portfolio:

LumiCoil PlatinumFiducial Markers:LumiCoil Platinum Fiducial Markers feature platinum construction designed for clear visibility in CT, X-Ray, EUS, CBCT, and MRI procedures. The use of fiducials may lead to more accurate targeting in delivery of radiation.

Theglobal Fiducial Markers marketreport would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising demand for fiducial manufacturers due to a rapid rise in cancer incidences
      • 4.1.1.2. The market's expansion is being further fueled by the increased awareness of radiation
    • 4.1.2. Restraints:
      • 4.1.2.1. Complications caused by the products are expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Composition

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 7.1.2. Market Attractiveness Index, By Product Composition
  • 7.2. Gold Markers
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 7.3. Polymer Markers
  • 7.4. Carbon Markers
  • 7.5. Platinum Markers
  • 7.6. Liquid Markers
  • 7.7. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Radiation Therapy
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. CT and CBCT Scans
  • 8.4. MRI and MEG Scans
  • 8.5. Endoscopic Ultrasound Scans
  • 8.6. Others

9. By Placement Locations

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 9.1.2. Market Attractiveness Index, By Placement Location
  • 9.2. Head and Neck
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 9.3. Breast
  • 9.4. Lung
  • 9.5. Abdomen
  • 9.6. Prostate
  • 9.7. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 10.3. Ambulatory Surgical Clinics
  • 10.4. Specialty Clinics
  • 10.5. Research Institutions

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size AnalysisUS$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Composition
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Placement Location
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), ByEnd User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Boston Scientific Corporation
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Medtronic Plc
  • 13.3. Nanovi A/S
  • 13.4. IBA Dosimetry
  • 13.5. Roper Technologies Inc.
  • 13.6. Guerbet SA
  • 13.7. Eckert & Ziegler BEBIG S.A.
  • 13.8. IZI Medical Products Inc.
  • 13.9. Naslund Medical AB
  • 13.10. MediTron SA.

LIST NOT EXHAUSTIVE

14. Global Fiducial Markers Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us